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Summary The current prognostic systems have failed to identify multiple myeloma (MM) patients who
require aggressive therapy. These staging systems do not reliably distinguish patients with different prognoses.
This paper explores the possibility of improving the prognostic forecast in MM by considering some clinical
characteristics at diagnosis together with response to first-line chemotherapy. A total of 231 patients were
prospectively randomised in a multicentre trial to no therapy vs melphalan + prednisone (MP) for stage I, MP
in stage II, and MP vs peptichemio, vincristine and prednisone for stage III. The clinical features of these
groups were evaluated for prognostic variables predictive of overall survival by means of univariate and
multivariate analysis. The independently significant variables were incorporated into a model that identified
three groups of patients with different risks of death and different overall survival. Three variables retained
statistical significance: the staging system proposed by the British Medical Research Council, a composite
parameter integrating the percentage of bone marrow plasma cells with cytological features of the infiltrating
elements (plasma cell vs plasmablast), and response to 6 months of first-line chemotherapy. These three
variables led the proposal of a scoring system able to identify three different risk classes (with median overall
survival of 52, 28 and 13 months respectively) and to estimate individual patient prognosis more flexibly. The
proposed risk classes, drawn from both diagnostic and therapeutic parameters, are thought to be a clinical and
investigational instrument for separating MM patients into comparable groups, for selecting the best available
therapy and for evaluating response with respect to the disease of each new patient.
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The survival duration of patients affected by multiple
myeloma (MM) has not varied significantly in the last 20
years (Alexanian and Dimopoulos, 1994). In spite of this
rather unsatisfactory situation, many current standard
regimens seem to have improved patient quality of life. The
results of myeloablative therapies followed by either
autologous or allogeneic bone marrow transplantation
(BMT) are promising but still burdened by uncertain
outcomes. These approaches require a more accurate
selection of the patients who would really benefit from such
treatments. At the same time, the currently available
prognostic criteria have never confirmed their actual
predictive ability in selecting subsets of MM patients for
different therapies.
There is considerable heterogeneity among the patient
series reported in the literature, but reliable comparisons are
only possible if patients are divided into well-defined and
reproducible groups. As our current staging systems are not
able to discriminate MM patients with different prognoses,
the results of newer therapies are destined to remain
controversial. Therefore we need more dependable instru-
ments to establish a basis for more reliable comparability.
Various authors have recognised this need (Niesvzky et al.,
1993; Greipp, 1992).
In order to overcome the present impasse involving MM
prognosis, we explored the possibility of integrating response
to first-line treatment (TR) together with one of the three
most common staging systems and other well-known clinical
features at diagnosis. TR proved to be a major prognostic
factor and allowed us to propose a new prognostic system for
MM patients.
Materials and methods
Study population
Between 1987 and 1989, 231 MM patients staged according
to Durie and Salmon (1975) were prospectively randomised
in a multicentre trial to the following therapies: no therapy vs
melphalan+prednisone (MP) for stage I patients, MP in
stage II and MP vs peptichemio, vincristine and prednisone
(PTC) (Riccardi et al., 1986) in stage III subjects. Patient
characteristics are described in Table I,
Patients were evaluated for response at the end of the first
6 months of induction therapy according to slightly modified
Table I Characteristics of the 231 evaluable patients
Mean age=65
Male= 120
Female= 111
Isotype
IgG= 132
IgA=55
IgD=0
IgE= 1
KIA =43
Stages
DS
1=44
II= 101
III = 86
MWJ
I =92
II =68
III = 71
BMRC
I=78
11= 124
III =29
DS, Durie and Salmon; MWJ, Merlini-Waldenstrom-Jayakar;
BMRC, British Medical Research Council.
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clinical criteria adopted by the Southern Cancer Study Group
(Cohen et al., 1986). Criteria were as follows: (a) reduction in
the monoclonal component (MC); (b) decrease in bone
marrow plasma cells (BMPC) of at least 20% or a return
to less than 20% as evaluated on bone marrow imprints
before and after treatment; (c) a >2 g dl-' rise in
haemoglobin (Hb) concentration in anaemic patients
(Hb<11 g dl-) sustained for more than 4 months; (d)
return of serum calcium and blood urea nitrogen (BUN) to
normal values; (e) elevation of serum albumin to 3 g dl-' or
higher in the absence of other causes of hypoalbuminaemia;
(f) absence of progression of skeletal lytic lesions.
Complete response (CR) was defined as a >50%
reduction in the MC and a response in more than half of
the other parameters. Partial response (PR) was a 25-50%
reduction in the MC and a response in more than half of the
other parameters. No response (NR) was defined as failure to
fulfil the above criteria for CR and PR. Progression was a
>25% increase in the MC and/or an increase in BMPC of at
least 20% and/or a worsening of laboratory parameters
(mainly haemoglobin, serum calcium, BUN) and/or skeletal
lytic lesions.
The median survival of patients in stage I was 58 months
(no therapy) vs 54 months (MP) (P=0.4701). The median
survival of patients in stage III was 31 months (MP) vs 34
months (PTC) (P=0.1274). The mean follow-up was 42
months. Furthermore, there were no statistically significant
differences between complete remission plus partial remission
vs no remission plus progression among the compared
groups. So we can conclude that the prognosis of our study
population was not heavily or differentially influenced by
therapy.
Statistical analysis
The following clinical and laboratory parameters were
measured at diagnosis and evaluated for prognostic rele-
vance: age, sex, haemoglobin (g dl-'), white blood cell count
(x1091-'), platelets (x 10'-'), serum creatinine (mg dl-'),
BUN (mg dl- ), calcium (mg dl-'), serum albumin (g dl-'),
MC (g dl-1), MC isotype, Bence-Jones proteinuria, hydro-
xyprolinuria (mg dl-1), serum alkaline phosphatase
(mU ml-'), erythrocyte sedimentation rate (ESR; mm/first
hour), serum 132-microglobulin (fl2M; jug ml-'), performance
status (according to the Karnofsky index scale), number of
lytic bone lesions, clinical stage according to three different
staging systems [Durie and Salmon, DS (Durie and Salmon,
1975); Merlini-Waldenstrom-Jayakar, MWJ (Merlini et al.,
1980); British Medical Research Council (Medical Research
Council's Working Party on Leukemia in Adults, 1980),
BMRC], bone marrow plasma cell percentage (BMI), bone
marrow plasma cell cytological feature (plasma cell vs
plasmablast) (Bartl et al., 1982) (BMC), bone marrow
infiltrate pattern (interstitial vs diffuse), osteoclastic activity
(low, intermediate, high), bone marrow fibrosis (low,
intermediate, high), bone marrow cellularity (ratio between
nucleate population and adipose tissue, graded as hypoplastic,
normal or hyperplastic).
Lastly, we studied the impact of TR on prognosis. This
unusual approach is supported by the following facts: (a)
many standard-dose combination chemotherapies were
compared with melphalan and prednisone (MP) but none
was shown to be superior (Gregory et al., 1992; Cooper et al.,
1986; MacLennan et al., 1988; Pavlovsky et al., 1988;
Tribalto et al., 1985) and thus MP still represents the
reference first-line chemotherapy; (b) response to conven-
tional chemotherapy is the most powerful prognostic factor
for patients undergoing either allogeneic (Gahrton et al.,
1993) or autologous BMT (Jagannath et al., 1990;
Dimopoulos et al., 1993; Fernand et al., 1993); (c) there is
a broad consensus among experts (Cunningham et al., 1994)
that the outcome of first-line therapy is the guideline for
deciding further treatment because unresponsive patients are
unlikely to benefit, in terms of survival, from additional
treatment; (d) as a matter of fact, response to 6 months of
treatment with either an alkylating agent plus prednisone or
combination chemotherapy was recently confirmed as a very
useful prognostic factor. (Guillemin et al., 1995). TR was
categorised as 0 for complete or partial remission, and as 1
for progression or stable disease.
Overall survival was computed according to Kaplan and
Meier (Kaplan and Meier, 1958). All deaths were considered
as events regardless of their cause. Each patient was
considered to be alive at the time of his/her last evaluation
unless death had been documented. Differences in overall
survival between groups were analysed using the log-rank test
and taking censored data into account.
Multivariate analysis of survival was performed using a
step-up selection procedure (Armitage and Berry, 1987) and
the Cox proportional hazards model (Cox, 1972). We
checked the goodness of fit of the selected models by means
of the Akaike information criterion (AIC) (Akaike, 1974).
Briefly, if lm is the log-likelihood of model m and dfm is the
degree of freedom of model m, then AIC =2 lm + 2 dfm. The
best model is the one with the lowest AIC value.
Results
The following prognostic variables were statistically signifi-
cant (P<0.05) at univariate analysis: age, sex, haemoglobin,
serum creatinine, BUN, serum calcium, serum albumin,
amount of the MC, Bence-Jones protein, hydroxyprolinuria,
serum alkaline phosphatase, ESR, #2M, Karnofsky perfor-
mance status, number of bone lytic bone lesions, stage
according to each of the three clinical systems, BMI, BMC,
bone marrow infiltrate pattern, bone marrow cellularity and
TR (Table II).
The log-likelihoods of the three staging systems, BMRC,
DS and MWJ, were not statistically different; nevertheless
BMRC staging showed the best log-likelihood and thus we
decided to adopt this system because of its relative simplicity
and greater reproducibility.
Table II Single-parameter analysis of prognostic variables
Parameter P-value
Age (years) 0.0016
Sex 0.0134
Haemoglobin (g 1-1) 0.0000
White blood cell Sx I0o 11) 0.1849
Platelets ( x 109 1 ) 0.2182
Serum creatinine (mg dl-1) 0.0164
Blood urea nitrogen (mg dl-1) 0.0001
Serum calcium (mg dl-1) 0.0098
Serum albumin (g dl-1) 0.0002
Monoclonal component (g dl-') 0.0043
Monoclonal component isotype 0.0673
Bence-Jones protein (+/-) 0.0001
Hydroxyprolinuria (mg dl-) 0.0062
Serum alkaline phosphatase (mU ml-l) 0.0189
Erythrocyte sedimentation rate (mm/first hour) 0.0001
Serum fl2-microglobulin (ig ml-1) 0.0001
Karnofsky performance index 0.0002
Number of lytic bone lesions 0.0001
Stage Durie-Salmon 0.0000
Stage Merlin-Waldenstrom-Jayakar 0.0000
Stage British Medical Research Council 0.0000
Bone marrow plasma cell percentage 0.0001
Bone marrow infiltrate cytology 0.0001
(plasma cell/plasmablastic)
Bone marrow infiltrate pattern 0.0006
(interstitial/diffuse)
Bone marrow fibrosis (low/intermediate/high) 0.0814
Bone marrow cellularity
(nucleate population/adipose tissue) 0.0561
Osteoclastic activity (low/intermediate/high) 0.1876
Response to therapy 0.0000Prognosis of myeloma
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Table Ill Multivariate analysis of significant variables
Parameter Log-likelihood P-value
Stage British Medical Research Council -649.230 0.0043
Bone marrow plasma cell percentage -643.664 0.0178
Bone marrow infiltrate cytology (plasma cell/plasmablastic) -640.356 0.0193
Bone marrow percentage and cytology of infiltrate (BMIC) -640.389 0.0198
Response to therapy (CR+PR vs progression) -628.146 0.0001
Since there were too many prognostic variables with
respect to the number of cases examined, we followed a step-
up procedure in our regression analysis. In other words, we
began our multivariate analysis by adding each single
parameter to BMRC stage.
All histopathological parameters examined were statisti-
cally significant at this first step of our procedure. We then
looked at whether any one of them provided more prognostic
information than the others. Two-BMI and BMC-were
found to be the only statistically significant ones in a
multivariate analysis of all the histopathological variables.
BMI was dichotomised according to its best cut-off value of
40% bone marrow infiltration and then combined with BMC
into a single variable called bone marrow infiltrate and
cytological type (BMIC), defined as follows: 0 if both are
favourable; 1 if either is unfavourable; 2 if both variables are
unfavourable.
Afterwards we repeated the analysis with the remaining
significant variables and found that only three ofthem retained
their importance: two characteristics at diagnosis, BMRC
stage and BMIC, and the 'ongoing' variable TR. A model
containing these three prognostic factors was then constructed
and it proved to be highly statistically significant (Table III).
Moreover, this model confirmed its validity when tested by
means of the Akaike information criterion (Table IV).
Since the relative risks associated with each of the
independently significant prognostic variables were compar-
able (Table V), the relative risk of death for a patient could
be characterised by adding the number of risk factors. We
propose a simple scoring system ranging from 0 to 5,
according to the combination of risk factors present. This
prognostic scoring is based on the patient's prognostic
variables at diagnosis -BMRC stage and BMIC-and his/
her TR evaluated after a 6 month period of conventional
chemotherapy, and is defined in this way: 0 for stage I,
positive response to treatment and favourable BMIC; 1 for
stage II, an intermediate BMIC and progression after first-
line treatment; 2 for stage III and unfavourable BMIC.
Scoring from 0 to 5 allows us to stratify patients into three
different classes of increasing risk: class I from 0 to 1; class II
equal to 2; class III from 3 to 5. The three classes have
remarkably dissimilar overall survival curves with highly
statistically significant differences (P<0.001) (Figure 1). The
median survival and death percentages per class are shown in
Table VI.
The Cox proportional hazards model was applied-as an
alternative analysis-to verify the results achieved by the
scoring system. The values of the ,B coefficients of the Cox
model are shown in Table VII. It is well known that these
coefficients are an estimate of the relative weight of each
covariate (i.e. each specific prognostic factor). Therefore the
Ps can be used to produce and evaluate another prognostic
index, called the MM index, which is derived by summing the
products of the value of each prognostic factor for the
corresponding # coefficient. The formula for this index is:
MM index =0.5 x BMRC (i.e. 1 or 2 or 3) +0.5 x BMIC (i.e.
1 or 2 or 3)+ 1.5 x TR (i.e. 1 or 2)
Thus a patient with a II BMRC stage, 60% bone marrow
involvement by a plasmablastic infiltrate and a poor response
to therapy would have an index of 5.5
(0.5 x 2 +0.5 x 3+1.5 x 2). This index, which ranges from
Table IV Akaike information criterion (AIC) (Akaike, 1974) of the
best prognostic indicators
Prognostic indicators Log-likelihood AIC
DS 615.669 1234.502
MWJ 616.147 1239.556
BMRC 610.669 1225.338
BMIC 611.362 1226.724
TR 613.794 1229.588
BMRC + BMIC 601.779 1223.558
BMRC+TR 601.035 1208.070
BMIC+TR 601.008 1208.016
BMRC + BMIC +TR 592.559 1192.118
Table V Relative risks of prognostic factors
Parameter Relative risk P-value
British Medical Research Council
Stage I vs stage II 3.34 <0.001
Stage II vs stage III 3.41 <0.001
BMIC
Favourable vs intermediate 2.94 <0.001
Intermediate vs unfavourable 2.97 <0.001
Response to treatment
(CR+PR) vs (progression +NR) 3.26 <0.001
.0 co -0
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Time (months)
72 84 96
Figure 1 Overall survival according to risk class.
2.5 to 6, allows a stratification that substantially confirms the
results obtained with the scoring system. The first group of
patients presents an index from 2.5 to 3; the second group
from 3.5 to 4; the third group of patients has an index of 4.5
or more. These three groups also show dissimilar overall
survivals with highly statistically significant differences
(Figure 2).
Discussion
The survival of patients with MM has not changed
substantially in the last 25 years. Thus, within a median
disease survival of about 3 years we find patients who live forPrognosis of myeloma
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10 years or even longer and others who die in less than 1
year. The search for a better definition of MM prognosis has
led to the development of many different staging systems and
the use of various prognostic factors. Most of them, while
promising, have failed to identify homogeneous and
reproducible risk classes of MM patients able to orient
treatment. It is therefore not surprising that recently
(Alexanian and Dimopoulos, 1994; Kyle, 1993) no criterion
was proposed other than the absence of symptoms for
deciding whether or not to treat a newly diagnosed MM,
regrdless of stage, labelling index, f32M, serum thymidine
kinase or any other clinical feature.
The lack of improvement in survival is mainly due to the
poor efficacy of our current therapies, both conventional and
myeloablative followed by stem cell rescue (regardless of
whether the source of the stem cell is the bone marrow-
allogeneic or autologous -or the peripheral blood). Never-
theless, the only long survivors are transplanted patients and
most of our efforts to cure MM rely upon some form of
transplantation (Kyle, 1993; Gahrton et al., 1991). It is thus
of great importance to avoid the risk of useless delays in
identifying a good candidate for this procedure.
None of the present prognostic instruments are reliable
enough to identify which patients should receive transplanta-
tion. One clinical and rather popular criterion is responsive-
ness to first-line chemotherapy. Indeed, on the other hand,
the probability of developing a multiresistant neoplastic clone
is enhanced by merely selective antineoplastic drug pressure
and, on the other hand, an early resistant MM patient will
probably not reach a complete remission even with
myeloablative regimens (Harousseau et al., 1992). Further-
more, experimental evidence demonstrates reduced mobilisa-
tion of peripheral blood stem cells in heavily pretreated
patients (Kotasek et al., 1992). As the peripheral blood stem
cell transplantation procedure seems to be the most
promising and widely appliable approach, early patient
selection could enhance the probability of success.
The aim of this work was to propose an improved tool
better able to stratify MM patients as soon as possible in
order to treat them with the best available therapy for their
disease. The following considerations illustrate the reasons
supporting our choice of prognostic variables and the
proposed risk classes or prognostic index.
independent role for f2M, which is the second parameter of
Bataille's system, when included in the analysis with the three
ultimately selected factors. This result surprised us because of
the general consensus regarding the prognostic importance of
/2M. Nevertheless, some authors did not find fl2M to be
significant (Fernand et al., 1993; Peest et al., 1993- Cunning-
ham et al., 1994; Blade 1993). We will briefly discuss the three
systems that were considered.
DS staging system evaluates the neoplastic mass with the
assumption that the higher the number of plasma cells the
poorer is prognosis. The MWJ staging system assumes an
exponential survival distribution for MM patients. This
property allows the authors to develope a parametric model
in which the immunoglobulins produced - IgG, IgA or light
chains K and A - are important prognostic factors. The
BMRC staging system considers the presence of symptoms
and 2 biochemical parameters: blood nitrogen and haemo-
globin concentrations.
In our analysis all the staging systems considered were
statistically significant at both univariate and multivariate
analysis. We chose the BMRC system for the following
reasons: (a) simplicity, (b) importance given to symptoms, (c)
best improvement in the log-likelihood in our multivariate
analysis by means of the Akaike information criterion.
Furthermore, some of us had already demonstrated the
relative superiority of BMRC over both DS and MWJ
(Gobbi et al., 1991).
The BMRC staging system describes the prognosis well in
our series, too. A major weakness of this staging system is
that it identifies too many patients as stage II. In our data the
distribution according to the BMRC staging system was:
30% (stage I); 55% (stage II); 15% (stage III). Our proposed
risk classes are sharper and separate BMRC stage II into
three almost equal classes (Table VIII). Table VIII also shows
how the survival and percentages of death among the
redistributed BMRC stage II patients are different.
BMIC
Many aspects of the cellular biology of MM escape our
comprehension. In particular, we do not know what the
proliferating cell is or where the MM stem cell comes from.
An understanding of these two questions would enhance our
grasp of the biology and clinical behaviour of this neoplasia.
BMRC stage
Among the many different proposed staging systems, we
studied three: DS, MWJ and BMRC. Each has its own
peculiarities resulting from the point of view from which it
explores the disease. Unfortunately, we had incomplete data
about C reactive protein so that we could not evaluate the
impact of a fourth staging system, that of Bataille (1992).
However, our multivariate analysis did not show an
._
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Table VI Risk classes
Median survival
Risk class Score (months) P-value Death (%)
Class I 0-1 52 59
0.0001
Class II 2 28 82
0.0001
Class III 3-5 13 98
0 12 24 36 48 60 72 84
Time (months)
Figure 2 Overall survival according to MM index.
Table VII Cox proportional hazards model
Parameter f, s.e. Exp-fl P-value
Stage British Medical Research Council (BMRC) 0.538191 0.1407727 1.712905 0.0013
Bone marrow percentage and cytology of infiltrate (BMIC) 0.468012 0.1124041 1.596817 0.0025
Response to therapy: (CR+PR) vs (progression+NR) (TR) 1.336513 0.2351125 3.805751 0.0001Prognosis of myeloma
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Table VIII Differences in distribution between the BMRC staging system and the risk classes
Death in BMRC
Risk class Median survival (months) BMRC staging system stage (%)
Class I 100 patients 52 1=60 57
II=40 62
I=13 79
Class II 66 patients 28 II=44 82
111=9 84
1=7 89
Class III 65 patients 13 I=40 94
III= 18 99
Nevertheless, it seems at least reasonable, as occurs for many
other tumours, that biology somehow correlates with the
tumour mass at diagnosis and with the characteristics of the
cells making up the mass itself. Since the first paper by Bartl
et al. (1982) MM histology and cytopathology have been
considered by many authors to be relevant prognostic factors
(Greipp et al., 1985; Bartl, 1988; Moro et al., 1992; Peest et
al., 1993; Sukpanichnant et al., 1994). In the present work we
considered many histopathological aspects, but only the
percentage of bone marrow infiltration by plasma cells and
the cytological features of this infiltrate retained statistical
significance in a multivariate model. Furthermore, we were
able to combine the 2 into 1 variable that expresses all the
prognostic variability owing to MM histopathology.
It is evident that a higher BMI means a reduced
environment for the normal components of the haemato-
poietic system. In addition, the kinetics of the MM clone is
slower than that of the normal haemopoietic cell lines
(Drewinko et al., 1981). This means that a higher percentage
ofinfiltration will generally be due to a longer presence of the
neoplasia. It is reasonable to think that the duration of the
disease roughly correlates with the damage produced by the
disease, with the number of cell duplications, and the risk of
cell mutation in the direction of drug resistance [according to
the so-called Goldie and Coldman hypothesis (Goldie and
Coldman, 1979)].
The grade of immaturity of the neoplastic cells is a
common oncological criterion for staging a tumour. This is
particularly true in haematology, as shown by the various
lymphoma or leukaemia classifications. The following
experimental evidence (Kubagawa et al., 1979; Pilarski et
al., 1985; Caligaris-Cappio et al., 1985, 1992; Epstein et al.,
1990) supports the prognostic role of the prevailing type of
cell: (a) plasma cells do not proliferate significantly; (b) in
most cases we do not find circulating plasma cells in
peripheral blood; (c) plasmablasts can circulate and, in the
suitable microenvironment, start to proliferate, secrete Ig and
differentiate to plasma cells. In other words, plasma cells are
probably responsible only for the damage produced by the
immunoglobulins secreted. Many authors (Fitz et al., 1984;
Carter et al., 1987; San Miguel et al., 1987; Paule et al., 1988;
Pasqualetti et al., 1990; Greipp, 1992) have shown the
survival advantage of plasmacytic vs plasmablastic type
MM but this aspect has not been considered in the design
and evaluation of clinical trials.
Response to treatment (TR)
Considering TR as a prognostic variable may seem a
tautology. It is self-evident that a responsive disease is more
likely to have a better outcome than a non-responsive one.
However, conventional chemotherapy does not have a major
impact on survival in MM because it cannot eradicate the
neoplastic clone. On the other hand, a response to therapy
indicates a disease that is not yet fully resistant. Such a
disease is still susceptible to cytoreduction with an
appropriate therapy. In other words, we do not know the
biological characteristics that make a cell 'resistant' to
therapy, but TR is a good indirect marker of those cellular
events that render a tumour composed mostly of cells either
responsive or non-responsive. Other authors (Bugliosi et al.,
1994; Gahrton et al., 1991; Jagannath et al., 1990; Attal et
al., 1992; Gore et al., 1989; Dimopoulos et al., 1993; Fernand
et al., 1993; Johnson and Selby, 1994; Guillemin et al., 1995)
have considered TR as a prognostic factor because of its
demonstrated importance on survival and on response to
further therapies (Dimopoulos et al., 1993; Fernand et al.,
1993). A recent report (Alexanian et al., 1994) showed that
myeloablative therapies are useless for MM patients in the
following three conditions: resistant relapse, primary
resistance longer than 1 year and relapse in consolidation
therapy of a late remission.
There is one more reason supporting TR as a prognostic
factor. MM is a neoplasm found in older people: the median
age at diagnosis is 68 (Riccardi et al., 1991; Longo, 1994).
Thus most of these patients cannot stand aggressive
chemotherapy. We still need an instrument to test the
potential responsiveness of those who are considered
candidates for myeloablative therapy. The efficacy of prior
standard chemotherapy could represent a means for selecting
those patients who deserve aggressive chemotherapy because
they will hopefully be long survivors and eventually be cured.
Scoring system as a clinical tool
We suggest that a direct clinical application of the proposed
risk classes could be in choosing the therapeutical strategy for
new patients. For example, the first class has a general
outcome that is similar to the average outcomes of
transplanted MM patients; however, the younger patients
(.55 years) in this class might derive additional benefit from
autologous transplantation-mostly from peripheral circulat-
ing progenitors (PCPs). The second class demonstrates a
much poorer outcome. When feasible, transplantation can be
attempted. In particular, depending on age and the
availability of an HLA compatible donor, allogeneic
transplantation seems to be appropriate; otherwise, if the
patient is less than 65 years old autologous transplantation
(preferentially from PCPs) can be considered. In our opinion,
the third class is not curable with the current therapeutical
strategies. Nevertheless, if the patient has a compatible donor
and an acceptable age, allogeneic transplantation probably
represents the only procedure able to offer some hope for this
class. So far, the results in this subset of patients have been
extremely poor.
The prognostic factors selected were used to construct two
different scoring systems (risk classes and MM index) that
ultimately corresponded to the same substantial prognostic
index. While the scoring systems are derived from different
approaches, the resulting prognostic index delineates three
groups of patients with very similar overall survival, as
shown in Figures 1 and 2. This is a relatively good
confirmation that the two prognostic systems identify the
same groups of patients with different risks.P*ognos of -
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For clinical use we have a slight preference for the risk
classes because of their greater simplicity. Nevertheless, the
MM index generated by the Cox analysis is equally sharp in
separating the different prognostic groups, and it offers a
matchless advantage for investigational uses. As a matter of
fact, the MM index can be employed as a distinct prognostic
covariate to be entered in a Cox's proportional hazards
regression model applied to a therapeutic trial. Such an
analysis would be simpler and easier. Most importantly, it
would allow good accuracy in evaluating clinical results even
in decidedly smaller samples. With this technique the MM
index covariate would synthetically summarise the whole
constellation of major and minor prognostic factors affecting
the course of MM, so that a simple clinical trial would need
no more than one other covariate: one expressing
'treatments'. to test the null hypothesis (e.g. no differences
between therapy A and B). Since the advisable number of
covariates in a Cox's model should be no more than 5-10%
of the number of events (deaths, null responses, relapses or
others), an anlysis that evaluates the goodness of a treatment
would be correct when 20-40 events have occurred. It is
evident that even small institutions will be able to reach such
a modest number ofevents and conclude a trial within a very
few years. This would enhance clinical research on MM by
lowering the number of patients necessary for individual
clinical studies on the effectiveness of a drug or a treatment
strategy.
Our approach is very empirical and clinically oriented, but
it offers a feasible, reliable solution for better-tailored therapy
until either new therapeutic devices or new biological markers
are able to permit better stratification of MM patients at
diagnosis.
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